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Backgrounds: Homozygous 32-bp deletion of the chemokine receptor 5 gene (CCR5) is associated with resistance to
human immunodeficiency virus (HIV) infection, while heterozygosity delays HIV progression. Bone marrow
transplantation (BMT) from a 32/32 donor has been shown to cure an HIV-infected patient. However, the rarity of this
mutation and the safety risks associated with current BMT protocols are the major obstacles to this treatment. Zinc finger
nuclease (ZFN) targeting is a powerful method for achieving genomic disruption at specific DNA sites of interest.
Results: Taking advantage of the self-renewal and plasticity properties of stem cells, in this study, we successfully generated
isogenic and six-cell clones of bone marrow-derived mesenchymal stem cells that carry the stop codon of the CCR5 gene
by using a ZFN-mediated homology-directed repair technique. These cells were expandable for more than 5 passages, and
thus show potential to serve as an individual’s cell factory. When Oct4 was overexpressed, the mutated cells robustly
converted to CD34+ progenitor cells.
Conclusion: We here reported the novel approach on generation of patients own CD34 cells from high fidelity
ZFN-mediated HDR MSC clones. We believe that our approach will be beneficial in future HIV treatment.
Keywords: Zinc finger nuclease, HIV, CCR5, Genome editing, Mesenchymal stem cellsBackground
Chemokine receptor 5 (CCR5) functions as a co-receptor for
human immunodeficiency virus (HIV) to enter into CD4
lymphocytes. Homozygosity of del32, a natural 32-bp dele-
tion of the CCR5 gene, confers strong resistance to HIV in-
fection, while heterozygosity of this deletion results in a
slower rate of HIV progression [1,2]. This finding suggested
that bone marrow transplantation (BMT) from a del32
donor may be a beneficial HIV treatment method [1]. In
2009, Hütter and colleagues reported the results of a BMT
from a del32/del32 donor to an HIV recipient [3]. Without
any anti-retroviral drugs, the patient’s CD4 lymphocytes in-
creased to normal levels and the virus remained undetectable
for at least five years of follow-up [4,5]. These data provided
strong evidence that HIV may be treatable, or at least be im-
proved, by cell therapy. Nevertheless, allogeneic BMT for the
treatment of HIV remains an impractical option. Since the* Correspondence: kmanotham@hotmail.com
Department of Medicine, Molecular and Cell Biology Unit, Lerdsin General
Hospital, Bangkok, Thailand
© 2015 Manotham et al.; licensee BioMed Cen
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.frequency of del32 is low in the general population, and par-
ticularly in non-Caucasians [6,7], finding a suitable donor for
each patient is not feasible. Moreover, the risks associated
with the immunosuppressive regimens required following
allogeneic BMT outweigh the risks associated with anti-HIV
drugs.
Therefore, inactivation of CCR5 by genetic manipulation
of a patients’ own cells is a good alternative to avoid the
drawbacks of donor shortage and immunosuppressive risks.
Zinc finger nuclease (ZFN) targeting has recently been
shown to be a promising method for disruption of genomic
DNA at very specific loci [8-12]. ZFN is a hybrid protein
consisting of an engineered DNA-binding zinc-finger, which
attaches to non-specific nuclease, FokI. A pair of ZFNs is de-
signed to specifically generate double-stranded breaks
(DSBs) in genomic DNA between each binding site. Subse-
quently, the chromosomal DSBs initiate an error-prone
repairing process known as non-homologous end-joining
(NHEJ), which often results in an InDel mutation around
the ZFN target site. Prezze’s and Holt’s research groups pio-
neered the use of ZFN-mediated InDel mutations in CCR5tral. This is an Open Access article distributed under the terms of the Creative
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(HSCs), respectively [13,14]. Unfortunately, NHEJ is an im-
precise process. InDel mutations are also unpredictable and
are theoretically not equivalent to loss of function.
Apart from NHEJ, DSBs can also be repaired through
a more precise mechanism known as homology-directed
repair (HDR), which enables integration of a desirable,
specific exogenous DNA sequence into the genome.
Many groups have reported success of ZFN-mediated
HDR in various human loci [10,15-17], including CCR5
[18-20]. This approach is therefore a promising tool
for mutation correction and site-specific gene inser-
tion. Of particular interest, in highly proliferative cells,
the use of ZFN homology base targeting was able to
generate the expandable clones even from a single
mutated cell [10,21]. A clone that carries the precise
amount of an edited genome is ideal for cell therapy.
Like drugs, the outcome as well as the toxicity of
these high-fidelity clones is adjustable and predictable.
Unfortunately, in vitro expansion of primary cell cul-
ture, including CD4 lymphocytes and HSCs, is limited;
hence, obtaining an ideal, patient-specific edited clone
population for therapeutic purposes has remained a
challenge.
Somatic stem cells are post-natal stem cells that have
very high self-renewal and differential capacity. Bone
marrow-derived mesenchymal stem cells (MSCs) are
well-established somatic stem cells that are easily ob-
tained through simple bone marrow aspiration [22,23].
The proliferation rate of MSCs is much higher than that
of CD4 lymphocytes and HSCs and may be the highest
among all primary cell cultures. Previous work has
also shown the feasibility of ZFN-mediated exogenous
gene insertion into CCR5 loci in MSCs [20]. Taken to-
gether, we speculated that it might be possible to generate
and enrich ZFN-mediated CCR5-specific gene integration
clones in MSCs.Recent progress in stem cell research has
demonstrated that cell phenotypes are (re)programmable.
In 2006, Takahashi and Yamanaka reported the successful
reprogramming of somatic cells into pluripotent cells via
induction with a set of transcription factors [24]. There-
fore, there is great interest in the potential combination of
cell reprogramming and ZFN-mediated gene editing
[21,25-28]. Apart from cell reprogramming, direct conver-
sion from one cell type to another is another interesting
approach that may have an additional advantage of genetic
stability [29]. Recently, fibroblasts were directly converted
to CD45+ HSCs by overexpressing Oct4 and then main-
taining the cells in defined media [30]. Collectively, these
findings led us to reason that cell conversion could be a
very powerful tool for future HIV treatment in conjunction
with ZFN-mediated HDR. To support our speculation, we
here report the generation of CD34+/CD45+ cells that orig-
inated from ZFN-mediated gene integration of MSCs.Methods
MSCs isolation and culture
MSCs were isolated from leftover bone marrow aspiration
samples, using a standard protocol [31]. The study
protocol was approved by the Ethic Committee of Lerdsin
General Hospital. The cells were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) (Gibco, Grand Island,
NY, U.S.A.) supplemented with 10% platelet lysate (Thai
Red Cross Society, Bangkok, Thailand) without antibiotics
[32]. Cells between passage 3 and 5 were used in the study.
For phenotypic characterization of MSCs, cells were har-
vested and washed in phosphate-buffered saline (PBS) buf-
fer. Then, 106 cells were resuspended in 100 μl PBS and
incubated with fluorescein isothiocyanate-, Phycoerythrin-,
or Phycoerythrin-Cy 7-conjugated monoclonal antibodies
against CD34, CD45, HLA-DR, HLA-ABC, CD79a, CD29,
CD33, CD44, CD73, CD90, and CD11b for 30 min at room
temperature. All antibodies were obtained from BD Biosci-
ences (San Diego, CA, USA). After incubation, excess anti-
bodies were washed off by adding PBS followed by
centrifugation at 2000 rpm for 5 min. Antibody-incubated
cells were resuspended in 200 μl of FACS solution and flow
cytometry was performed by using a FACS Calibur system
(BD Biosciences). The data were analyzed with Cell Quest
Pro software (BD Biosciences). Adipogenic and osteogenic
differentiation were induced with Human Mesenchymal
Stem Cell Functional Identification Kit (R&D system,
Minneapolis, MN, USA).
Immunohistochemistry and immunofluorescence analysis
For immunostaining, cells were cultured in 4-well chamber
slides and fixed with −20°C methanol:acetone (1:1) for
10 min. The cells were then incubated with 3% H2O2 to
quench endogenous peroxidases, as previously described
[33]. Primary antibodies for osteocalcin and Oct4 (Cell sig-
naling, Danvers, MA, USA) were applied in 1% bovine
serum albumin with 0.1% Tween in PBS (dilution 1:500)
for 1 h at room temperature, followed by incubation with
biotinylated secondary antibodies for 30 min. Either
avidin peroxidase or avidin-Alexa Fluor conjugates
were applied at the final step. Images were captured with
the Olympus BX51 and Olympus DP71 systems (Olympus;
Tokyo, Japan).
Generation of the donor plasmids
cDNA of human CCR5 (1791 bp), from −733 bp upstream
of the left-hand ZFN-binding site to 1038 bp downstream
of the right-hand ZFN-binding site, was amplified from
genomic DNA of peripheral blood using the primers D1
(5′-GTGGACAGGGAAGCTAGCAG-3′) and D2 (5′-CC
ATACCTTGGAGGGGAAAT-3′). The polymerase chain
reaction (PCR) products were ligated into a TA cloning
vector (RBC TA Cloning Vector Kit, RBC Bioscience;
Taipei, Taiwan). Next, the ligated vectors were transformed
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Technologies; Santa Clara, CA, USA) and subjected to
sequencing analysis. We designed the universal stop
codon “TAGATAGTTAG” and inserted it between two
ZFN-binding sites by PCR-induced mutagenesis (Agilent
Technologies). The insertion was confirmed by DNA
sequencing and the plasmid was designated as d-stop
plasmids (Figure 1).
Editing of CCR5 in MSCs with ZFN
CCR5-specific ZFN mRNA was purchased from Sigma
Aldrich (St. Louis, MO, USA). The ZFN was designed to
target the third exon of CCR5, as previously described [13].
In some experiments, we synthesized the pair of ZFN
mRNAs from a plasmid by using the Massagemax™ T7
mRNA transcription and Poly (A) polymerase tailing kit
(Epicentre; Madison, WI, USA). The ZFN mRNA pair and
d-plasmid were transfected to MSCs with Nucleofector
(Neon; Invitrogen; Carlsbad, CA, USA). Cells were cul-
tured for 5 days after transfection, and were then trypsi-
nized and replated into 96-well plates at a density of 1 cell/
well or 6 cells/well. Cells in 96-well plates were examined
on a daily basis. After growing to a 70% confluent mono-
layer, MSCs from the single-cell or six-cell wells were tryp-
sinized and transferred to two 3-cm Petri dishes.
Nested PCR screening for HDR-mediated stop codon
insertion
Genomic DNA was extracted from confluent 3-cm culture
plates that originated from single-cell or six-cell clones
with a genomic DNA extraction kit (RBC Bioscience). The
extracted DNA was then subjected to nested PCR. The
first round of amplification was carried out with primers
E2 (5′-CTGAGACATCCGTTCCCCTA-3′; −1744 bp up-
stream of D1) and P2 (5′-TGTAGGGAGCCCAGAA
GAGA-3′). Once the first round was complete, the second
round of PCR was established with an insertion-specificFigure 1 Primers map and donor plasmid generation. Illustration of the
sequence (underlined) and the interspace. Lower panel: DNA sequences of
(IP); a silent T-A mutation adjacent to the left ZFN-targeted site was intenti
integration between the ZFN-binding sites.primer (IP) (5′-TGGCTAACTATCTAAA-3′) and P1 (5′-
TTAAAAGCCAGGACGGTCAC-3′) (Figure 1). The PCR
products were electrophoresed on 1.5% agarose gel (Prona-
disa; Madrid, Spain) and visualized under ultraviolet light.
To assess the amount of stop codon integration in the ex-
pandable six-cell clones, the genomic sequence of CCR5
was amplified using the P1/P2 primer pair. PCR products
were ligated to TA cloning vector (RCB Bioscience) and
transformed into E. coli. The bacteria colonies were picked
up and amplified with the P1, P2, and IP primers. The ra-
tios of double 152-bp and 346 + 11 (357)-bp bands, which
represented of stop codon insertion per successful trans-
formation, which represented by total of single 346-bp and
double 152-bp,357-bp bands, were then calculated.
Genomic gene sequencing
To confirm the presence of the inserted sequence, PCR
products of positively screened single- and six-cell clones
were ligated and transformed into E. coli competent cells.
Plasmid DNA from each colony was extracted and sub-
jected to direct sequencing or reamplification with the
P1/P2 primer pair before sequencing. The sequencing
was carried out by Macrogen Company (Seoul, Korea).
Hematopoietic progenitor conversion of gene-edited MSC
clones
A retroviral vector encoding human Octamer-binding
transcription factor 4 (Oct4) was purchased from Cell Bio-
labs (San Diego, CA, USA). The vector was transfection to
Plat-A packaging cells with X-fect reagent (Clontech;
Mountain View, CA, USA) for retrovirus construction.
Forty-eight hours after vector transfection, the virions were
harvested and concentrated with Retro-X™ Concentrator
(Clontech). Direct conversion of gene-edited MSCs to
hematopoietic progenitor cells was carried out in five inde-
pendent experiment (2 mutated six-cell clones and 3 native
MSCs).Ten thousand of native MSCs or MSCs fromCCR5 locus and primer locations. Upper panel: ZFN-targeted DNA
the d-plasmid around the ZFN site and the insertion-specific primer
onally selected for confirmation and marking of the vicinity of
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coated flasks and cultured in DMEM/F-12 supplemented
with 10% fetal bovine serum (FBS; Gibco; Grand Island,
NY, USA). Twenty-four hours after plating, cells were in-
fected with a retrovirus expressing human Oct 4 cDNA by
polybrene (Sigma). One day after infection, culture media
containing the virus were replaced with reprogramming
media (RM) (DMEM/F-12 supplemented with 10% FBS
and 100 units/ml penicillin G-streptomycin, 0.1 mM
β-mercaptoethanol,16 ng/ml basic fibroblast growth factor
[R&D Systems], 30 ng/ml insulin-like growth factor-2,
300 ng/ml Flt3, and 300 ng/ml stem cell factor). Mutated
and non-mutated MSCs that overexpressed human Oct4
and the control MSCs that were maintained in RM were
analyzed by flow cytometry (FACS Calibur; BD Biosci-
ences) on day 14.
Results
Isolation and characterization of MSCs
We isolated MSCs from leftover bone marrow aspiration
specimens that were used for hematologic diagnosis of
four donors (Table 1). Flow cytometry analysis showed
that these cells were positive for mesenchymal surface
markers such as CD29, CD44, CD73, CD90, and HLA-
ABC and were negative for CD11b, CD34, D45, CD79a,
and HLA-DR (Figure 2a.). These cells were able to differ-
entiate into adipocyte and osteocyte lineages, as shown in
Figure 2b,c and d. Immunohistochemistry suggested that
these cells did not express CCR5 (Figure 2e).
Direct generation of isogenic ZFN-mediated stop codon
CCR5 clones
A total of 2 × 106 MSCs (passage 3–5) were transfected
with mRNA encoding ZFNs targeting the CCR5 gene along
with the d-stop plasmid by nucleoporation. Five days after
gene transfection, MSCs were trypsinized and replated in
96-well plates at a density of one cell per well. A total of
4320 single-cell cultures were established (3 donors, 8 in-
dependent experiments). The cultured cells gradually prop-
agated and expanded. By the 8th week, only 88 clones that
originated from a single cell successfully expanded to reach
an 80% confluent monolayer in two 3-cm dishes. Nested
PCR screening revealed that 2 of the 88 clones carried the
insertion sequence in the CCR5 locus (Figure 3a). Genomic
sequencing confirmed that both isogenic clones contained
the single-allele HDR-mediated stop codon insertionTable 1 Patient details
Patient Clinical setting
1 Male, HIV+, with thrombocytopenia, ARVs+
2 Female, HIV+, with pancytopenia, ARVs+
3 Female, ERSD, with erythropoietin unresponsive anem
4 Male, Alcoholic cirrhosis with thrombocytopenia, HIV(Figure 3b). However, neither of the inserted clones could
propagate beyond two passages in 25-ml flasks (≈0.8
million-fold). This might be due to the expansion limit of
MSCs [31].
Generation of ZFN-mediated stop codon CCR5 six-cell
clones
Previous studies indicated that the proliferation of MSCs
depends on the initial seeding density [34]. To circumvent
the limited expansion observed in single-cell clones and to
enhance ex vivo enrichment, we, therefore, increased the
initial density to six cells/well. From two donors, we set up
three independent gene-editing experiments in an attempt
to generate a total of 986 six-cell clones. Of these, 42 six-
cell clones were generated within four weeks and were
screened for stop codon insertion. Nested PCR screening
showed that four clones had the inserted stop codon in the
CCR5 locus. Of these, two clones were expandable in a 25-
ml flask. Unlike the single-cell clones, these six-cell clones
were able to further expand in the 25-ml flask beyond five
passages (at a 1:2 split) before the proliferation rate de-
creased (≈1 million-fold). The insertion was stably detected
at all five passages. The ratios of double PCR products per
transformation success in the two clones at 3rd passage
(≈7 weeks after ZFN editing) were 12.2% and 13.3%, re-
spectively (Figure 3c). Although, our estimation method of
gene integration might be confounded if the donor plasmid
were present in the established clones. However, after
7 weeks of expansion culture, it was unlikely that TA clon-
ing vector still retained and contributed to 12-13%of PCR
products. Taken together, the result suggested that both
clones initially had only one cell with a single allele of
HDR-mediated gene insertion.
Conversion of native MSCs and edited MSC clones to
CD45+/CD34+ cells
In order to support the practical utility of the mutated CCR5
MSCs, we next converted the mutated cells to CD34+
cells by infection with a retrovirus encoding Oct4. Im-
munofluorescence analysis at 24 h after infection dem-
onstrated that approximately 60% of the MSCs
expressed Oct4, mostly in the cytoplasm (Figure 4a).
Around day 7–10 after infection, small colonies of cells
began to appear before rapidly proliferating and expanding
(Figure 4b). Cells from the expanding colonies were
smaller and rounder than normal MSCs (Figure 4c). TheseSingle-cell clone Six-cells clone
1 Not done
0 Not done
ia, HIV- 1 1
+, ARV- Not done 3
Figure 2 Basic properties of MSCs. a) Flow cytometry analysis of MSCs. b) Adipocyte differentiation as shown by positive Oil Red O lipid
accumulation in the cytoplasm. c) MSCs expressed osteocalcin in the cytoplasm after osteogenic differentiation was induced. d) Calcium
deposition in MSCs after osteogenic differentiation demonstrated by Alizarin Red staining. e) Immunohistochemistry of CCR5 showed that the
MSCs were negative for CCR5 expression.
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Figure 3 PCR screening and DNA sequencing. a) Nested PCR showing the positive clones in lane 5 and 10. b) DNA sequence of
isogenic single-cell and six-cell clones. (Note the A→ T mutation in one of the isogenic clones). c) PCR products of CCR5 from picked-up colonies;
the double bands indicated the existence of an HR-mediated mutation (arrow; indicated the lower band), while the single band indicated the
presence of the CCR5 sequence in the bacteria colonies. The ratios of double/total of single and double band were 12.2%and 13.3%, suggesting
that both six-cell clones initially carried only one mutation of 12 alleles.
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to the Matrigel-coated plate. The proportion of round
cells peaked at day 14 before decreasing at day 21.
Flow cytometry analysis at day 14 post-infection showed
an increase in CD34+ cells (Figure 4d) in Oct4-transfectedFigure 4 Direct cell conversion by Oct4. a) Immunofluorescence of Oct4
the mutated colonies at day 7–10 after Oct4 infection. c) Small cells that ra
of flow cytometry of a six-cell-mutated clone at day 14, showing the emerg
to the six-cell-mutated control.MSCs as compared to the nontransfected clones. Cells ex-
pressing the pan-leukocyte marker CD45 also increased in
parallel with CD34+ cells; at day 14, approximately 33.6%
of the cells showed double-positive expression of CD34
and CD45.at 24 h after infection. b) Representative picture of the appearance of
pidly expanded from the emerging colonies. d) Representative image
ence of CD34+ and CD45+ cells in Oct4 transduced cells as compared
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The progress related to the use of ZFN-edited CCR5 for
potential HIV treatment has been very rapid. A number of
studies have confirmed the reproducible success of genome
editing of CCR5 loci in various cell types and with the use
of different methods [10-14,19,25,35-42]. Currently, ZFN
editing of patients’ own CD4 lymphocytes has moved into
phase I trials, and new methods for incorporating this
technique to large scales are currently under investigation
[38,39]. Since genome editing occurs individually in each
cell, the key factors for the success of this technique with
respect to clinical applications are the editing efficacy and
the expansion ability of the edited progeny cells. Recently,
the InDel mutation of CD34+ cells has been reported
[14,40,41]. Unlike CD4 lymphocytes, which are terminally
differentiated cells and thus have limited ability for in vivo
proliferation, CD34+ HSCs can regenerate entire bone
marrow populations. Therefore, their potential to function
as an autologous BMT source for HIV treatment seems
very promising. It is known that the success of BMT de-
pends on the CD34+ cell dose [41]; hence, generating a
critical number of edited CD34 cells is a key factor to the
success of this technique for treatment. Unfortunately, the
in vitro expansion of CD34 cells is relatively restricted, and
thus would not be suitable for clonal generation.
The advantages of stem cells are their unlimited self-
renewal and broad ability of differentiation. In the present
study, we took advantage of these properties of bone
marrow-derived MSCs to generate CD34+ clones that car-
ried an HDR-mediated stop codon insertion of CCR5, an
important co-receptor for HIV to enter the cell, without
using selectable markers. While this work was in progress,
Yao’s group employed ZFN to integrate exogenous green
fluorescent protein into CCR5 loci of induced pluripotent
stem cell (iPSC) and embryonic stem cell lines [26]. Using
PCR screening, the authors estimated that the rate of
HDR-mediated gene integration was remarkably high in
both cell lines. Of particular interest, the edited cells could
further differentiate into CD34 cells and hematologic
lineage cells. Theoretically, Yao’s approach can produce
patient-specific isogenic CD34 cells for therapeutic pur-
poses; however, expanding HSCs from iPSCs remains a
technically difficult task.
In our work, with mRNA-based ZFN-mediated HDR, we
could obtain only 6 expandable cells out of 10,236
attempted cells that carried one allele of gene insertion;
therefore, the yield of our experimental conditions should
not be lower than 0.059%. Despite the fact that this yield is
lower than that obtained with other methods of ZFN/
donor delivery, we clearly showed that the proliferation of
MSCs is high enough to overcome the low initial yield. It is
also possible that employing either drug or marker selec-
tion might increase the number of positive clones; how-
ever, we consider that the use of a direct clone selectionmethod is more straightforward and safe for future clinical
applications. The recent emergence of new genome-editing
tools, transcription activator-like effector nucleases (TALEN)
and clustered regularly interspaced short palindromic
repeats (CRISPR), is of interest in this respect [37,42].
Several reports have shown that the efficiency of gen-
ome disruption with both methods was higher than that
of ZFN, which might help to improve the overall yield.
We also evaluated the feasibility of using the mutated
MSC clones for HIV treatment by converting these cells
to CD34+ cells. In the pioneer work on direct conver-
sion of fibroblasts to HSCs, the investigators found that
the number of CD45+/CD34+ cells had significantly in-
creased 3 weeks after overexpression of Oct4 was in-
duced [30]. Recent work from the same group further
clarified that both Oct4 and culture media, RM, were
crucial for the conversion and maintenance of the HSC
phenotype [43]. In our work, both native and ZFN-
edited MSCs expressed CD34 after induction with Oct4
and culture in RM. Of particular note, a significant num-
ber of CD34+ cells showed co-expression of CD45 anti-
gens; both antigens are important surface markers of the
hematologic lineage and are always negative in MSCs,
indicating successful lineage conversion. However, it
should also be noted that the retrovirus mediating Oct4
is not safe for clinical use and single allele of CCR5 dis-
ruption is insufficient to inhibit viral entering. Nonethe-
less, these results demonstrate the great potential of this
approach in future HIV treatment.
Conclusion
We here reported the novel approach on generation of pa-
tients own CD34 cells from high fidelity ZFN-mediated
HDR MSC clones. We believe that our approach will be
beneficial in future HIV treatment.
Abbreviations
ARV: Antiretroviral drug; BMT: Bone marrow transplantation;
CCR5: Chemokine receptor 5; DMEM: Dulbecco’s modified Eagle’s medium;
DSB: Double-strand break; HDR: Homology-directed repair; HIV: Human
immunodeficiency virus; HLA: Human leukocyte antigen; HSC: Hematopoietic
stem cell; MSC: Mesenchymal stem cell; NHEJ: Non-homologous end-joining;
PBS: Phosphate-buffered saline; PCR: Polymerase chain reaction;
Oct4: Octamer-binding transcription factor 4; ZFN: Zinc finger nuclease.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
KM designed the study, conducted the experiment and prepared
manuscript. SC performed experiments and data analysis. AS obtained
funding and refined the manuscript. All authors read and approved the final
version of the manuscript.
Acknowledgements
We are grateful to Dr. Ryoji Sassa (Okasaki, Nagoya) for his generous support.
This work was supported by a grant from Thanpuying Lursakdi Sampatisiri
and Lerdsin Foundation.
Manotham et al. Journal of Biomedical Science  (2015) 22:25 Page 8 of 8Received: 2 December 2014 Accepted: 19 March 2015References
1. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, et al.
Genetic restriction of HIV-1 infection and progression to AIDS by a deletion
allele of the CKR5 structural gene. Hemophilia growth and development
study, multicenter AIDS cohort study, multicenter hemophilia cohort study,
San Francisco city cohort, ALIVE study. Science. 1996;273:1856–62.
2. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, et al.
Homozygous defect in HIV-1 coreceptor accounts for resistance of some
multiply-exposed individuals to HIV-1 infection. Cell. 1996;86:367–77.
3. Hütter G, Nowak D, Mossner M, Ganepola S, Müssig A, Allers K, et al.
Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell
transplantation. N Engl J Med. 2009;360:692–8.
4. Allers K, Hütter G, Hofmann J, Loddenkemper C, Rieger K, Thiel E, et al.
Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell
transplantation. Blood. 2011;117:2791–9.
5. Yukl SA, Boritz E, Busch M, Bentsen C, Chun TW, Douek D, et al. Challenges
in detecting HIV persistence during potentially curative interventions:
a study of the Berlin patient. PLoS Pathog. 2013;9:e1003347.
6. Novembre J, Galvani AP, Slatkin M. The geographic spread of the CCR5
Delta32 HIV-resistance allele. PLoS Biol. 2005;3:e339.
7. Cohn Jr SK, Weaver LT. The Black Death and AIDS: CCR5-Delta32 in genetics
and history. QJM. 2006;99:497–503.
8. Bibikova M, Beumer K, Trautman JK, Carroll D. Enhancing gene targeting
with designed zinc finger nucleases. Science. 2003;300:764.
9. Carroll D. Progress and prospects: zinc-finger nucleases as gene therapy
agents. Gene Ther. 2008;15:1463–8.
10. Urnov FD, Miller JC, Lee YL, Beausejour CM, Rock JM, Augustus S, et al.
Highly efficient endogenous human gene correction using designed
zinc-finger nucleases. Nature. 2005;435:646–51.
11. Santiago Y, Chan E, Liu PQ, Orlando S, Zhang L, Urnov FD, et al. Targeted
gene knockout in mammalian cells by using engineered zinc-finger
nucleases. Proc Natl Acad Sci. 2008;105:5809–14.
12. Urnov FD, Rebar EJ, Holmes MC, Zhang HS, Gregory PD. Genome
editing with engineered zinc finger nucleases. Nat Rev Genet.
2010;11:636–46.
13. Perez EE, Wang J, Miller JC, Jouvenot Y, Kim KA, Liu O, et al. Establishment
of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger
nucleases. Nat Biotech. 2008;7:808–16.
14. Holt N, Wang J, Kim K, Friedman G, Wang X, Taupin V, et al. Human
hematopoietic stem/progenitor cells modified by zinc-finger nucleases
targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol. 2010;28:839–47.
15. Porteus MH, Baltimore D. Chimeric nucleases stimulate gene targeting in
human cells. Science. 2003;300:763.
16. Moehle EA, Rock JM, Lee YL, Jouvenot Y, DeKelver RC, Gregory PD, et al.
Targeted gene addition into a specified location in the human genome
using designed zinc finger nucleases. Proc Natl Acad Sci U S A.
2007;104:3055–60.
17. Maeder ML, Thibodeau-Beganny S, Osiak A, Wright DA, Anthony RM,
Eichtinger M, et al. Rapid “open-source” engineering of customized
zinc-finger nucleases for highly efficient gene modification. Mol Cell.
2008;31:294–301.
18. DeKelver RC, Choi VM, Moehle EA, Paschon DE, Hockemeyer D, Meijsing SH,
et al. Functional genomics, proteomics, and regulatory DNA analysis in
isogenic settings using zinc finger nuclease-driven transgenesis into a safe
harbor locus in the human genome. Genome Res. 2010;8:1133–42.
19. Kandavelou K, Ramalingam S, London V, Mani M, Wu J, Alexeev V, et al.
Targeted manipulation of mammalian genomes using designed zinc finger
nucleases. Biochem Biophys Res Commun. 2009;388:56–61.
20. Benabdallah BF, Allard E, Yao S, Friedman G, Friedman G, Gregory PD, et al.
Targeted gene addition to human mesenchymal stromal cells as a
cell-based plasma-soluble protein delivery platform. Cytotherapy.
2010;12:394–49.
21. Soldner F, Laganière J, Cheng AW, Hockemeyer D, Gao Q, Alagappan R,
et al. Generation of isogenic pluripotent stem cells differing exclusively at
two early onset Parkinson point mutations. Cell. 2011;146:318–31.
22. Friedenstein AJ, Gorskaja JF, Kulagina NN. Fibroblast precursors in normal
and irradiated mouse hematopoietic organs. Exp Hematol. 1976;4:267–74.23. Castro-Malaspina H, Gay RE, Resnick G, Kapoor N, Meyers P, Chiarieri D, et al.
Characterization of human bone marrow fibroblast colony-forming cells
(CFU-F) and their progeny. Blood. 1980;56:289–301.
24. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse
embryonic and adult fibroblast cultures by defined factors. Cell.
2006;126:663–76.
25. Tay FC, Tan WK, Goh SL, Ramachandra CJ, Lau CH, Zhu H, et al. Targeted
transgene insertion into the AAVS1 locus driven by baculoviral
vector-mediated zinc finger nuclease expression in human-induced
pluripotent stem cells. J Gene Med. 2013;15:384–95.
26. Yao Y, Nashun B, Zhou T, Qin L, Qin L, Zhao S, et al. Generation of
CD34+ cells from CCR5-disrupted human embryonic and induced
pluripotent stem cells. Hum Gene Ther. 2012;23:23842.
27. Miyaoka Y, Chan AH, Judge LM, Yoo J, Huang M, Nguyen TD, et al. Isolation
of single-base genome-edited human iPS cells without antibiotic selection.
Nat Methods. 2014;11:291–3.
28. Ramalingam S, London V, Kandavelou K, Cebotaru L, Guggino W, Civin C,
et al. Generation and genetic engineering of human induced pluripotent
stem cells using designed zinc finger nucleases. Stem Cells Dev.
2013;22:595–610.
29. Graf T, Enver T. Forcing cells to change lineages. Nature. 2009;462:587–94.
30. Szabo E, Rampalli S, Risueño RM, Schnerch A, Mitchell R, Fiebig-Comyn A,
et al. Direct conversion of human fibroblasts to multilineage blood
progenitors. Nature. 2010;468:521–6.
31. Smith JR, Pochampally R, Perry A, Hsu SC, Prockop DJ. Isolation of a highly
clonogenic and multipotential subfraction of adult stem cells from bone
marrow stroma. Stem Cells. 2001;22:823–31.
32. Capelli C, Domenghini M, Borleri G, Bellavita P, Poma R, Carobbio A, et al.
Human platelet lysate allows expansion and clinical grade production of
mesenchymal stromal cells from small samples of bone marrow aspirates or
marrow filter washouts. Bone Marrow Transplant. 2007;40:785–91.
33. Manotham K, Tanaka T, Matsumoto M, Ohse T, Inagi R, Miyata T, et al.
Transdifferentiation of cultured tubular cells induced by hypoxia. Kidney Int.
2004;65:871–80.
34. Halleux C, Sottile V, Gasser JA, Seuwen K. Multi-lineage potential of human
mesenchymal stem cells following clonal expansion. J Musculoskelet
Neuronal Interact. 2001;2:71–6.
35. Kim HJ, Lee HJ, Kim H, Cho SW, Kim JS. Targeted genome editing in human
cells with zinc finger nucleases constructed via modular assembly. Genome
Res. 2009;19:1279–88.
36. Lombardo A, Genovese P, Beausejour CM, Colleoni S, Lee YL, Kim KA, et al. Gene
editing in human stem cells using zinc finger nucleases and integrase-defective
lentiviral vector delivery. Nat Biotechnol. 2007;25:1298–306.
37. Kim H, Kim MS, Wee G, Lee CI, Kim H, Kim JS. Magnetic separation and
antibiotics selection enable enrichment of cells with ZFN/TALEN-induced
mutations. PLoS One. 2013;8:e56476.
38. Tebas P, Stein D, Tang WW, Frank I, Wang SQ, Lee G, et al. Gene editing of
CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med.
2014;370:901–10.
39. Maier DA, Brennan AL, Jiang S, Binder-Scholl GK, Lee G, Plesa G, et al.
Efficient clinical scale gene modification via zinc finger nuclease-targeted
disruption of the HIV co-receptor CCR5. Hum Gene Ther. 2013;24:245–58.
40. Li L, Krymskaya L, Wang J, Henley J, Rao A, Cao LF, et al. Genomic editing of
the HIV-1 coreceptor CCR5 in adult hematopoietic stem and progenitor
cells using zinc finger nucleases. Mol Ther. 2013;21:1259–69.
41. Ketterer N, Salles G, Raba M, Espinouse D, Sonet A, Tremisi P, et al. High
CD34(+) cell counts decrease hematologic toxicity of autologous peripheral
blood progenitor cell transplantation. Blood. 1998;91:3148–55.
42. Ye L, Wang J, Beyer AI, Teque F, Cradick TJ, Qi Z, et al. Seamless
modification of wild-type induced pluripotent stem cells to the natural
CCR5Δ32 mutation confers resistance to HIV infection. Proc Natl Acad Sci
U S A. 2014;111:9591–6.
43. Mitchell R, Szabo E, Shapovalova Z, Aslostovar L, Makondo K, Bhatia M.
Molecular evidence for OCT4 induced plasticity in adult human fibroblasts
required for direct cell fate conversion to lineage specific progenitors.
Stem Cells. 2014;32:2178–87.
